Orthofix also reported net income of $14.0 million for this quarter, up from $10.5 million in the prior year. The company also reported 7 percent growth in net sales for its spine business to $81.8 million, while net sales from its orthopedic business decreased 6 percent to $37.7 million.
During the second quarter, increased adoption of the Trinity Evolution in spine applications led to a 48 percent increase in sales of the regenerative biologics business.
More Articles on Orthopedic Devices:
Minimally Invasive Surgery Market to Reach $35.5B by 2016
MiMedx Revenues Reach $4.9M in 2Q, 153% Increase
China Device Market Expected Grew at 20.5% CAGR From 2006-2011
